Roth Capital Has Positive Forecast for BRTX FY2024 Earnings

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Analysts at Roth Capital upped their FY2024 earnings per share (EPS) estimates for BioRestorative Therapies in a research report issued on Thursday, November 14th. Roth Capital analyst J. Aschoff now forecasts that the company will earn ($1.43) per share for the year, up from their previous estimate of ($1.76). The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.43) per share. Roth Capital also issued estimates for BioRestorative Therapies’ Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.86) EPS, FY2026 earnings at ($0.83) EPS and FY2027 earnings at $3.43 EPS.

BioRestorative Therapies (NASDAQ:BRTX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.22. BioRestorative Therapies had a negative net margin of 2,697.08% and a negative return on equity of 98.49%. The business had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.30 million.

Separately, Roth Mkm lifted their price objective on BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th.

BioRestorative Therapies Stock Down 4.8 %

BRTX stock opened at $1.38 on Monday. The company has a market cap of $9.55 million, a price-to-earnings ratio of -0.95 and a beta of 63.40. The business has a fifty day simple moving average of $1.63 and a 200-day simple moving average of $1.60. BioRestorative Therapies has a 52 week low of $1.03 and a 52 week high of $3.67.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.